Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
Completed
- Conditions
- Contraception
- Interventions
- Drug: BAY98-7071_EE20/DRSP/L-5-MTHF
- Registration Number
- NCT02159261
- Lead Sponsor
- Bayer
- Brief Summary
Local prospective multicenter non-comparative non-interventional observational study. It's planed to assess satisfaction of patients and physicians with results of Yaz Plus treatment for 13 cycles in real practice.
- Detailed Description
Non-interventional, Yaz Plus, Contraception, Assess satisfaction, Russian Federation.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1500
Inclusion Criteria
- Female patients ≥ 18 years old
- Requiring contraception
- Prescribed with Yaz Plus for the first time
Exclusion Criteria
- Contraindications for the use of Yaz Plus in accordance with the local product information
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort 1 BAY98-7071_EE20/DRSP/L-5-MTHF Female patients ≥ 18 years old requiring contraception.
- Primary Outcome Measures
Name Time Method Satisfaction measured with a Likert response scale (from 1 - poor to 5 - excellent) Up to 12 months
- Secondary Outcome Measures
Name Time Method Changes in EVAPIL scale for assessment of tolerability of oral contraceptives. Baseline to 12 months Number of participants with adverse events as a measure of safety and tolerability Up to 12 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Yaz Plus (EE20/DRSP/L-5-MTHF) contraceptive efficacy and satisfaction in NCT02159261?
How does Yaz Plus compare to standard combined oral contraceptives in patient-reported satisfaction metrics?
Which biomarkers correlate with improved satisfaction outcomes in Yaz Plus users for contraceptive management?
What adverse events were observed in NCT02159261 and how do they align with Bayer's contraceptive safety profiles?
How does the L-5-MTHF component in Yaz Plus influence contraceptive adherence versus folic acid-supplemented COCs?